Who owns natalizumab patents, and what do they cover?
Natalizumab is marketed as Tysabri, a monoclonal antibody used for relapsing multiple sclerosis and Crohn’s disease. Patent coverage for a biologic typically spans multiple “layers,” such as composition-of-matter, formulation/manufacturing, and method-of-use claims. The practical impact is that even when the original (or key) patent expires, additional patents on specific claim scopes can delay competition.
When does natalizumab’s main patent expire?
I don’t have enough provided information to state specific natalizumab patent expiry dates or which patent(s) control the remaining exclusivity. Natalizumab’s “last” effective date can also depend on the jurisdiction (e.g., US vs. EU vs. UK), patent term adjustments, and regulatory exclusivity terms tied to biologics.
If you share the country (US/EU/UK/etc.) and whether you mean patent expiry or regulatory exclusivity (or both), I can narrow down what “expiration” you should look for.
Why can natalizumab remain protected even after an early patent expires?
For biologics, protection often continues through additional patents that cover things like:
- manufacturing/process or analytics changes required for commercialization
- specific therapeutic dosing or patient subgroups
- formulation stability and delivery characteristics
This can create a gap where one patent ends but other patents still block biosimilar/competitor entry in that jurisdiction.
Are there biosimilars of natalizumab, and how do patents affect their launch?
Natalizumab’s patent situation directly affects whether biosimilars can enter when they are approved. Even if a biosimilar is authorized, courts or patent “stay” mechanisms can delay commercial launch until key patents expire or are found not infringed/not valid.
To answer precisely, I’d need the jurisdiction and the specific patents or product you’re comparing against.
How do you check the natalizumab patent landscape quickly?
The fastest way to identify controlling patents is usually to look up:
- the branded product’s listed patents in the relevant regulatory system (varies by country)
- the patent family(s) behind the original molecule and subsequent improvement filings
- any litigation that indicates which patents are actually being enforced
If you tell me the country and whether you want “patents only” or “patents plus exclusivity,” I can outline the exact search targets (and what to look for) for that system.
What happens if a patent is challenged or found invalid?
If a competitor challenges a patent, the key outcomes are:
- the patent is invalidated (competition may proceed sooner)
- the court narrows the claim scope (competitors may still need non-infringing designs)
- the patent remains enforceable (entry is delayed)
Patent challenges often become the determining factor for launch timing rather than the scheduled nominal expiry alone.
What’s the difference between “patent expiry” and “regulatory exclusivity” for natalizumab?
Patent expiry is a legal end date for specific claims. Regulatory exclusivity can prevent approval or commercialization even if some patents expire, depending on local laws and the biologic’s authorization pathway. For biologics, both concepts can shape when biosimilars can actually be sold.
Tell me what you need and I’ll pull the exact expiry details
To give a concrete answer (dates and which patents), tell me:
1) Which jurisdiction: US, EU, UK, or another country
2) Do you want the earliest patent expiry, the “last” controlling expiry, or regulatory exclusivity too?
3) Are you asking about natalizumab specifically (Tysabri) or a biosimilar competitor?
Sources
No sources were provided in the prompt, so I didn’t cite any.